News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Evotec AG (EVTG.F) Wins Research Grant to Advance H3 Receptor Antagonist Programme Into the Clinic



4/27/2010 12:41:44 PM

HAMBURG, Germany, April 27, 2010 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it will receive funding of up to EUR 1.5 million from the German Federal Ministry of Education and Research (BMBF) to advance its H3 receptor antagonist programme into the clinic.

Read at GlobeNewswire


comments powered by Disqus
Evotec AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES